Literature DB >> 33794595

The initial experience of COVID-19 vaccination from a tertiary care centre of India.

R K Srivastava1, Pranav Ish2, Safdarjung Covid-Vaccination Group3.   

Abstract

To the Editor Drugs Controller General of India (DCGI) has approved the Bharat biotech vaccine against COVID-19, which is a locally manufactured inactivated vaccine named ''COVAXIN'' in collaboration with the Indian council of medical research (ICMR) on 3rd  January 2021 for emergency use along with the "Covishield" Oxford-AstraZeneca vaccine manufactured locally by the Serum Institute of India... *The Safdarjung COVID-19 Vaccination group: KR Meena (Professor, Paediatrics), U Venkatesh (Assistant Professor, Community Medicine), Pushpa Kumari (Associate Professor, Medicine), Sonal Burman (Specialist, Medicine), Neeraj Kumar Gupta (Professor and Head, Pulmonary Medicine), Nitesh Gupta (Assistant Professor, Pulmonary Medicine), Rohit Kumar (Assistant Professor, Pulmonary Medicine), Swetabh Purohit (Senior resident, Pulmonary Medicine), Arjun Ramaswamy (Senior resident, Pulmonary Medicine).

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33794595     DOI： 10.4081/monaldi.2021.1816

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN： 1122-0643


  8 in total

Review 1.  Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges.

Authors:  Ramesh Kandimalla; Pratik Chakraborty; Jayalakshmi Vallamkondu; Anupama Chaudhary; Sonalinandini Samanta; P Hemachandra Reddy; Vincenzo De Feo; Saikat Dewanjee
Journal:  Biomedicines       Date:  2021-11-22

2.  Collateral Impact on Patients of Liver Diseases in the Second COVID-19 Wave: A Retrospective Cohort Study.

Authors:  Chitranshu Vashishtha; Ankit Bhardwaj; Amita Diwaker; Shivakshi Sharma; Manoj K Sharma; Shiv Sarin
Journal:  Cureus       Date:  2022-05-31

3.  Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students-which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?

Authors:  Behzad Houshmand; Seied Omid Keyhan; Hamid Reza Fallahi; Shaqayeq Ramezanzade; Erfan Sadeghi; Parisa Yousefi
Journal:  Maxillofac Plast Reconstr Surg       Date:  2022-01-13

4.  Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study.

Authors:  Prativa Subedi; Gopal Kumar Yadav; Binod Paudel; Anu Regmi; Prajjwal Pyakurel
Journal:  PLoS One       Date:  2021-12-21       Impact factor: 3.240

5.  Tackling the Roadblocks to COVID-19 Vaccination in India - The Need of the Hour.

Authors:  Pranav Ish; Shreyash Agrawal; Kanishk Sinha
Journal:  Indian J Occup Environ Med       Date:  2021-12-31

6.  Response to comment on: Facial nerve palsy after COVID-19 vaccination - A rare association or coincidence.

Authors:  Somya Ish; Pranav Ish
Journal:  Indian J Ophthalmol       Date:  2022-01       Impact factor: 1.848

Review 7.  Adverse Events following Immunization with COVID-19 Vaccines: A Narrative Review.

Authors:  Bijay Bhandari; Gaurav Rayamajhi; Pratik Lamichhane; Ashok K Shenoy
Journal:  Biomed Res Int       Date:  2022-08-16       Impact factor: 3.246

8.  Facial nerve palsy after COVID-19 vaccination - A rare association or a coincidence.

Authors:  Somya Ish; Pranav Ish
Journal:  Indian J Ophthalmol       Date:  2021-09       Impact factor: 1.848
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.